Product Description
For Hematological Malignancy (Sourced from: http://www.dizalpharma.com/innovation/P&S)
Mechanisms of Action: BCR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Chronic Lymphoid Leukemia *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dizal Pharmaceuticals
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Italy, United States
Active Clinical Trial Count: 12
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma|Lymphoma, B-Cell
Phase 2: Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07294365 |
TAI-SHAN11 | P2 |
Recruiting |
Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic |
2027-07-01 |
50% |
2026-01-23 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06539195 |
TAI-SHAN9 | P2 |
Active, not recruiting |
Diffuse Large B-Cell Lymphoma |
2026-01-01 |
12% |
2025-12-13 |
|
NCT06539182 |
TAI-SHAN8 | P2 |
Recruiting |
Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2027-09-01 |
12% |
2024-08-07 |
Primary Endpoints|Treatments |
2025-522669-32-00 |
DZ2024B0002 | P3 |
Not yet recruiting |
Lymphoma|Chronic Lymphoid Leukemia |
2028-11-30 |
|||
NCT05824585 |
DZ2022B0002 | P1 |
Recruiting |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2027-04-30 |
50% |
2024-07-24 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments|Trial Status |
CTR20240120 |
CTR20240120 | P2 |
Recruiting |
Lymphoma|Chronic Lymphoid Leukemia |
None |
2025-05-11 |
Patient Enrollment|Treatments |
|
CTR20240121 |
CTR20240121 | P2 |
Active, not recruiting |
Diffuse Large B-Cell Lymphoma |
None |
2025-12-21 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
NCT07139873 |
TAI-SHAN6 | P3 |
Recruiting |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma, B-Cell |
2029-01-01 |
21% |
2025-11-19 |
Primary Endpoints|Start Date|Treatments|Trial Status |
CTR20250291 |
CTR20250291 | P1 |
Completed |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2025-04-03 |
2025-08-05 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT07059650 |
TAI-SHAN12 | P2 |
Recruiting |
Diffuse Large B-Cell Lymphoma |
2030-10-01 |
12% |
2025-08-29 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07154264 |
TAI-SHAN10 | P2 |
Recruiting |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell |
2029-12-01 |
12% |
2025-11-18 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT05844956 |
TAI-SHAN1 | P2 |
Completed |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2024-02-29 |
70% |
2025-02-22 |
Primary Endpoints |